Research programme: rhinovirus inhibitors - eXegenics
Alternative Names: Rhinovirus infections research programme - eXegenicsLatest Information Update: 21 Aug 2003
At a glance
- Originator eXegenics
- Class
- Mechanism of Action Rhinovirus 3C protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 21 Aug 2003 Discontinued - Preclinical for Rhinovirus infections in USA (unspecified route)
- 01 Aug 2003 Suspended - Preclinical for Rhinovirus infections in USA (unspecified route)
- 09 Nov 2001 Cytoclonal Pharmaceutics is now called eXegenics